Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy.

The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection.Click here to read more.